What is replacing BPC 157? A Look at Leading Peptide Alternatives
•
4 min read
Following recent crackdowns and cautions by the U.S. Food and Drug Administration (FDA), the experimental peptide BPC 157 is facing significant regulatory hurdles, causing many in the regenerative medicine field to seek out approved alternatives. The shift away from BPC 157 is driven by a lack of rigorous human clinical data and safety concerns, prompting increased interest in other well-researched peptides like Pentadeca Arginate (PDA) and TB-500.
